Drug Trial Radar · NCT07336446
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Actual
Start
Jan 27, 2026
Primary completion
Nov 5, 2026
Study completion Nov 5, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.
Conditions
- Prostate Cancer
Interventions
AZD9750Drug
AR-PROTAC
AZD5305Drug
PARP1-selective inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only)Time frame: From first dose of study intervention to 28 days post first dose
- Number of participants with Adverse Events and Serious Adverse EventsTime frame: From first dose of study intervention up to 37 days after the last dose of study treatment
- Number of participants with Adverse Events leading to discontinuation of study interventionTime frame: From first dose of study intervention up to 37 days after the last dose of study treatment
- Clinically significant changes from baseline in vital signs.Time frame: From first study dose up to 37 days after the last dose of study treatment
- Clinically significant changes from baseline in physical examination.Time frame: From first dose of study intervention up to 37 days after the last dose of study treatment
- Clinically significant changes from baseline in ECOG PS.Time frame: From first dose of study intervention up to 37 days after the last dose of study treatment
- Clinically significant changes from baseline in ECGs.Time frame: From first dose of study intervention up to 37 days after the last dose of study treatment
- Clinically significant changes from baseline in laboratory parameters.Time frame: From first dose of study intervention up to 37 days after the last dose of study treatment
- Proportion of participants achieving a ≥50% decrease in PSA from baseline (PSA50) (Part B only)Time frame: From first dose of study intervention up to 14 days after the last dose of study treatment
Locations
5 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California
Research Site
Nashville, Tennessee
Research Site
Melbourne, Australia
Research Site
Kashiwa, Japan
Research Site
Cambridge, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.